Strategy

Our mission and strategy 

Our mission

Our mission is to pioneer and deliver next-generation treatments offering the potential to prevent vision loss. We have pioneered the drug category of pharmacological vitreolysis with JETREA®, the world’s first and only pharmacological treatment approved for symptomatic vitreomacular adhesion/ vitreomacular traction. We will develop other solutions and expand this category.

With diabetes being a leading health challenge worldwide, we are committed to deliver new and innovative treatments to help tackle the growing number of diabetes-related eye diseases.

We want to provide solutions enabling vision preservation for all people equally. The patient is at the focus of all we do: when a treatment is good for a patient, eventually it will benefit all the company’s stakeholders, internally and externally.

Strategy

Broadening its global footprint as a drug development pioneer in back of the eye disorders, with a focus on diabetic eye disease

We will expand our work in earlier-stage projects, searching for new pathways and compounds for developing next-generation treatments for back of the eye disorders with a focus on diabetic eye disease: diabetic retinopathy (non-proliferative DR - NPDR, proliferative DR - PDR), with and without diabetic macular edema (DME).

Early 2016, a Phase II clinical study to assess ocriplasmin’s (THR-409) utility for treatment of NPDR was initiated.
A Phase I/IIa clinical study evaluation of THR-317 (anti-PlGF) for the treatment of DME is planned for initiation around year end 2016.
ThromboGenics constantly seeks to broaden its franchise in ophthalmology and beyond, through both in-house research and strategic acquisitions, joint development, and licensing deals.

Commercializing JETREA® on global scale (in first approved indication, symptomatic VMA/VMT) in the US and RoW via partner Alcon (Novartis)

Jetrea packagingEvery day, more people benefit from JETREA®, the first pharmacological treatment for symptomatic VMA/VMT. JETREA® has now been approved in 54 countries worldwide.

ThromboGenics Inc. will continue to commercialize JETREA® and supply the product via a well-established distribution network. The team provides medical and scientific data-driven support to the retina community.

In Europe and the rest of the world (RoW), our partner Alcon/Novartis continues to gain new marketing and reimbursement approvals and execute commercial launches of JETREA® for treatment of VMT.

 

Realizing value from Oncurious NV, a new oncology company with ThromboGenics as a major shareholder

In April 2015, ThromboGenics’ oncology R&D work was incorporated in a separate entity: Oncurious NV, a joint venture with the Flanders Institute for Oncurious logoBiotechnology (VIB). Oncurious is leveraging the joint expertise to develop innovative medicines for treating pediatric brain tumors.